Short description
Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases.
Description
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Lexington, Massachusetts, United States, North America
Founded on
January 1, 2003
Exited on
March 28, 2014
Went public on
March 28, 2014
Stock symbol
PULM
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Cannot Access, Noaccessforu, Absolutely Noaccess, Noaccessforu, Blurry Noaccess, Blurry Noaccess
Sign in for full access
Founders
Alexander Klibanov, Mark J. Gabrielson